Felzartamab in AMR (2024) — Trial Summary
Felzartamab in AMR (2024): This phase 2, double-blind, randomized, placebo-controlled trial evaluated felzartamab, a CD38 monoclonal antibody, in kidney transplant recipients with late antibody-mediated rejection (AMR) occurring at least 180 days after transplantation.
References
- Mayer KA, Schrezenmeier E, Diebold M, et al. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. N Engl J Med. 2024;391(2):122-132.